Clostridium difficile Infection

被引：114

作者：

Heinlen, Latisha ^{[2
]}

Ballard, Jimmy D. ^{[1
]}

机构：

[1] Univ Oklahoma, Hlth Sci Ctr, Dept Microbiol & Immunol, Oklahoma City, OK 73104 USA

[2] Univ Oklahoma, Hlth Sci Ctr, Dept Internal Med, Oklahoma City, OK 73104 USA

来源：

AMERICAN JOURNAL OF THE MEDICAL SCIENCES | 2010年 / 340卷 / 03期

关键词：

Clostridium difficile; Toxin; Hospital-associated diarrhea; PROTON-PUMP INHIBITORS; TOXIC MEGACOLON SECONDARY; SERUM ANTIBODY-RESPONSE; SACCHAROMYCES-BOULARDII; DOUBLE-BLIND; RISK-FACTOR; DIARRHEA; VANCOMYCIN; DISEASE; COMMUNITY;

D O I：

10.1097/MAJ.0b013e3181e939d8

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Clostridium difficile is the leading cause of hospital-acquired diarrhea in Europe and North America and is a serious reemerging pathogen. Recent outbreaks have led to increasing morbidity and mortality and have been associated with a new strain (BI/NAP1/027) of C difficile that produces more toxin than historic strains. With the increasing incidence of C difficile infection, clinicians have also seen a change in the epidemiology with increased infections in previously low-risk populations. This chapter highlights the current knowledge on C difficile virulence, human disease, epidemic outbreaks and optimal treatment strategies.

引用

页码：247 / 252

页数：6

共 93 条

[1] Fulminant Clostridium difficile colitis [J].

Adams, Sasha D. ;

Mercer, David W. .

CURRENT OPINION IN CRITICAL CARE, 2007, 13 (04) :450-455

[2] Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease [J].

Al-Nassir, Wafa N. ;

Sethi, Ajay K. ;

Li, Yuejin ;

Pultz, Michael J. ;

Riggs, Michelle M. ;

Donskey, Curtis J. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (07) :2403-2406

[3] SERUM ANTIBODY-RESPONSE TO CLOSTRIDIUM DIFFICILE TOXINS IN PATIENTS WITH CLOSTRIDIUM DIFFICILE DIARRHEA [J].

ARONSSON, B ;

GRANSTROM, M ;

MOLLBY, R ;

NORD, CE .

INFECTION, 1985, 13 (03) :97-101

[4] Gastric Acid Suppression by Proton Pump Inhibitors as a Risk Factor for Clostridium difficile-Associated Diarrhea in Hospitalized Patients [J].

Aseeri, Mohammed ;

Schroeder, Todd ;

Kramer, Joan ;

Zackula, Rosalee .

AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 (09) :2308-2313

[5] Tolevamer Is Not Efficacious in the Neutralization of Cytotoxin in a Human Gut Model of Clostridium difficile Infection [J].

Baines, Simon D. ;

Freeman, Jane ;

Wilcox, Mark H. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (05) :2202-2204

[6] Fecal bacteriotherapy for recurrent Clostridium difficile infection [J].

Bakken, Johan S. .

ANAEROBE, 2009, 15 (06) :285-289

[7] CLOSTRIDIUM-DIFFICILE - HISTORY OF ITS ROLE AS AN ENTERIC PATHOGEN AND THE CURRENT STATE OF KNOWLEDGE ABOUT THE ORGANISM [J].

BARTLETT, JG .

CLINICAL INFECTIOUS DISEASES, 1994, 18 :S265-S272

[8]

BARTLETT JG, 1978, GASTROENTEROLOGY, V75, P778

[9] Clinical recognition and diagnosis of Clostridium difficile infection [J].

Bartlett, John G. ;

Gerding, Dale N. .

CLINICAL INFECTIOUS DISEASES, 2008, 46 :S12-S18

[10] Fungemia with Saccharomyces cerevisiae after treatment with Saccharomyces boulardii [J].

Bassetti, S ;

Frei, R ;

Zimmerli, W .

AMERICAN JOURNAL OF MEDICINE, 1998, 105 (01) :71-72

← 1 2 3 4 5 6 7 8 9 10 →